Opus Genetics, Inc. (IRD) disclosed that Dr. Ashwath Jayagopal will transition from his role as the company's Chief Scientific and Development Officer. The company has entered into a separation agreement that includes a six-month consulting arrangement for transition services.
Key Details
- Departing Executive: Dr. Ashwath Jayagopal, Chief Scientific and Development Officer.
- Effective Date: The transition was effective as of October 19, 2026.
- Consulting Agreement: Dr. Jayagopal will provide transition services for six months at a compensation rate of $250 per hour. His outstanding vested options will remain exercisable during the consulting period.